Fourth Quarter 2016 GAAP net earnings of $0.34
per diluted share compared to $0.96 for the fourth quarter of
2015Fourth Quarter 2016 Non-GAAP net earnings of $0.34 per diluted
share compared to $0.44 for the fourth quarter of 2015Year ended
December 31, 2016 GAAP net loss of $0.24 per diluted share
compared to net earnings of $1.98 for the year ended
December 31, 2015Year ended December 31, 2016 Non-GAAP
net earnings of $1.72 per diluted share compared to $1.47 for the
year ended December 31, 2015
Chemtura Corporation (NYSE:CHMT) (Euronext Paris:CHMT) (the
“Company,” “Chemtura,” “We,” “Us” or “Our”) today announced
financial results for the fourth quarter and year ended
December 31, 2016. The Company also filed with the
Securities and Exchange Commission its Annual Report on Form 10-K
for the year ended December 31, 2016. For the fourth
quarter of 2016, Chemtura reported net sales of $385 million and
net earnings on a GAAP basis of $22 million, or $0.34 per diluted
share. Net earnings on a Non-GAAP basis were $22 million, or
$0.34 per diluted share. For the year ended December 31,
2016, Chemtura reported net sales of $1,654 million and a net loss
on a GAAP basis of $15 million, or $0.24 per diluted share.
Net earnings on a Non-GAAP basis were $111 million, or $1.72 per
diluted share.
Fourth Quarter 2016 Financial
Results
The discussion below includes financial information
on both a GAAP and non-GAAP basis. Later in this release, we
explain our Non-GAAP metrics including how each is calculated, why
we use the specific metric and the internal controls around our
Non-GAAP metrics. We have provided reconciliations of our
GAAP financial information to our Non-GAAP financial metrics in the
supplemental schedules attached to this release. The use of
Non-GAAP metrics is not a substitute for GAAP measures and should
not be considered as such.
The following is a summary of the unaudited
financial results on a GAAP and Non-GAAP basis (a description of
our Non-GAAP metrics appears later in this release):
(In
millions, except per share data) |
|
Quarters Ended - GAAP |
|
Quarters Ended - Non- GAAP |
|
|
December 31, 2016 |
December 31, 2015 |
% change |
|
December 31, 2016 |
December 31, 2015 |
% change |
Net sales |
|
$ |
385 |
|
$ |
399 |
|
(4 |
%) |
|
$ |
376 |
|
$ |
390 |
|
(4 |
%) |
Operating income |
|
$ |
41 |
|
$ |
36 |
|
14 |
% |
|
|
|
|
|
Net earnings |
|
$ |
22 |
|
$ |
66 |
|
(67 |
%) |
|
$ |
22 |
|
$ |
30 |
|
(27 |
%) |
Net earnings - per
diluted share |
|
$ |
0.34 |
|
$ |
0.96 |
|
(65 |
%) |
|
$ |
0.34 |
|
$ |
0.44 |
|
(23 |
%) |
Adjusted EBITDA |
|
|
|
|
|
$ |
59 |
|
$ |
55 |
|
7 |
% |
|
|
|
|
|
|
|
|
|
|
|
Years Ended - GAAP |
|
Years Ended - Non- GAAP |
|
|
December 31, 2016 |
December 31, 2015 |
% change |
|
December 31, 2016 |
December 31, 2015 |
% change |
Net sales |
|
$ |
1,654 |
|
$ |
1,745 |
|
(5 |
%) |
|
$ |
1,616 |
|
$ |
1,707 |
|
(5 |
%) |
Operating income |
|
$ |
46 |
|
$ |
162 |
|
(72 |
%) |
|
|
|
|
|
Net (loss)
earnings |
|
$ |
(15 |
) |
$ |
136 |
|
(111 |
%) |
|
$ |
111 |
|
$ |
101 |
|
10 |
% |
Net (loss) earnings -
per diluted share |
|
$ |
(0.24 |
) |
$ |
1.98 |
|
(112 |
%) |
|
$ |
1.72 |
|
$ |
1.47 |
|
17 |
% |
Adjusted EBITDA |
|
|
|
|
|
$ |
282 |
|
$ |
237 |
|
19 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CEO Remarks
“In the fourth quarter, we focused on finishing the
year strong and on progressing towards closing the Lanxess
transaction,” said Craig Rogerson, Chemtura's Chairman, President
and Chief Executive Officer. “We are pleased that our
shareholders have overwhelmingly approved the merger with Lanxess
and that we have already received a number of regulatory
clearances. The post-closing integration planning is on
course and our respective organizations are well positioned to
create a stronger, more diverse and higher performing specialty
chemical company.”
Mr. Rogerson continued, “In the fourth quarter, we
were able to continue our strong 2016 performance. Fourth
quarter operating income increased 14% versus the prior year on
overall lower revenue. Sequentially, revenue and operating
income were lower for our industrial businesses, which is often the
case in the last quarter of the year. For the full year,
excluding the impact of the pension settlement charge incurred
earlier in the year and the expenses related to the merger and
post-closing integration planning, 2016 operating income increased
36% over our 2015 results.”
“Our IEP Segment posted higher fourth quarter
revenue and operating income compared to the fourth quarter of
2015,” said Mr. Rogerson. “Higher prices for bromine-based
products and increased sales of our polymer co-catalyst products
led the way for IEP’s year-over-year improvements. Also, in
2015, IEP’s fourth quarter performance was dragged down by charges
related to exiting a product line, which did not repeat in the
fourth quarter of 2016. Sequentially, revenue and operating
income were lower compared to the third quarter of 2016 due in part
to lower bromine sales in the U.S., lower sales of clear brine
fluids and seasonally lower fumigant sales. It is worth
noting that sales of flame retardants, such as tetrabrom, into
certain electronic applications increased sequentially.”
“Our IPP Segment reported lower fourth quarter
sales and operating income compared to prior year and sequentially.
Year-over-year declines in IPP sales and operating income are
attributable to unfavorable product mix and lower demand across
many of our IPP product lines. We also saw lower prices in
certain IPP products compared to last year, as we passed along
lower raw material costs to certain of our customers. In
addition, sales prices for urethanes products used in mining and
oil and gas applications were lower in the fourth quarter of 2016
compared to last year due to continued weakness in those
industries, although we did experience volume growth from new
urethane applications in Asia. Sequential declines in IPP
sales and operating income were predominately due to year-end order
timing, unfavorable product mix and higher raw material and
manufacturing costs.”
“For the calendar year of 2016, we delivered on our
commitment to increase operating profitability,” observed Mr.
Rogerson. “Excluding the first quarter pension settlement
charge resulting from the pension annuity transaction and merger
and integration costs, 2016 operating profit of $221 million
increased by $59 million, or 36% compared to 2015 calendar year
operating profit of $162 million. The improvement was less
visible in our earnings per share due to the loss from the pension
settlement charge, the merger and integration expenses and the 2015
tax benefit from certain tax credits and the release of valuation
allowance which resulted in a lower than normal tax rate for the
prior year.”
Mr. Rogerson concluded, “Looking ahead, we will
continue to work with our Lanxess colleagues to ensure a smooth
transition and integration into the Lanxess organization
post-closing. We expect that the transaction will close by
the middle of 2017. We will also continue to execute on our
business plan.”
Pending Merger Transaction with
Lanxess
On February 1, 2017, Chemtura's stockholders voted
to approve and adopt the agreement and plan of merger (the "Merger
Agreement") we entered into on September 25, 2016 with Lanxess
Deutschland GmbH, a limited liability company under the laws of
Germany ("Lanxess"), and LANXESS Additives Inc., a Delaware
corporation and an indirect, wholly owned subsidiary of Lanxess
("Merger Subsidiary"). The merger remains subject to
customary closing conditions. Assuming timely satisfaction of
the remaining closing conditions, we currently expect the merger to
close by mid-2017.
Fourth Quarter Overview - GAAP
See tables that follow for a quantitative summary
of the components of change by segment between the fourth quarter
of 2016 and the fourth quarter of 2015 (“year-over-year”) and
compared to the third quarter of 2016 (“sequential”).
Industrial Performance Products (“IPP”)
Our IPP segment delivered lower net sales and lower
operating income both year-over-year and sequentially.
Year-over-year, the reduction in net sales was
primarily the result of lower volume and lower sales prices.
During 2016, we continued to pass along the benefit of lower raw
material costs to certain of our customers where required by
contract. Lower volume and unfavorable product mix in our
petroleum additive products, particularly in synthetic lubricants,
base stocks and detergents, were partially offset by increased
sales of our lower priced intermediate products. New
application demand for our urethane products, particularly in Asia,
offset the continued low demand for our urethane products used in
mining and oil and gas applications that we experienced all
year. Sequentially, the primary drivers of the decline in net
sales were lower volumes and unfavorable product mix. In the
third quarter of 2016, we benefited from additional volume for our
inhibitor products due to a temporary shutdown of an Asian
competitor's plant. With production restored, demand returned
to normal levels in the fourth quarter, although seasonally
lower. Sales prices showed a modest increase over the
previous quarter.
Operating income year-over-year benefited from
favorable raw material and distribution costs which were offset by
the lower volume and unfavorable product mix and higher costs for
manufacturing, inventory adjustments and selling, general and
administrative ("SG&A"). Sequentially, the impact of
lower net sales, coupled with higher costs for raw material,
manufacturing and inventory adjustments in the fourth quarter,
reduced operating income.
Industrial Engineered Products (“IEP”)
Our IEP segment reported an improvement in
year-over-year net sales and operating income. On a
sequential basis, our IEP segment reported lower net sales and
lower operating income.
Year-over-year, the increase in net sales was
primarily driven by higher sales prices in our Emerald Innovation
3000TM products, as well as in our bromine and bromine-based
derivative products. We saw a significant improvement in
volume for our organometallic polymerization co-catalysts and tin
specialty products due to increased customer demand, which was
offset in part by slower demand for our Emerald Innovation 3000TM
product and the reduced demand for our clear brine fluids used in
the drilling of deep offshore oil and gas wells that we have
experienced all year. Sequentially, the benefit of increases
in sales prices for bromine and bromine-based derivatives and tin
specialty products were partly offset by some competitive
reductions in sales prices for certain brominated flame retardant
products. Sales volumes benefited from increased demand for
tetrabrom which was completely offset by the reduced demand for
clear brine fluids, fumigants and bromine and bromine-based
derivative products.
Operating income on a year-over-year basis
benefited from the higher sales prices and the volume improvement
in our organometallic products. Lower raw material costs in
certain products were offset by the higher cost of tin, which in
many cases we were able to pass along to our customers under
formula-based pricing. Unfavorable manufacturing and
absorption variances in 2016 were offset by the absence of a charge
we recorded in the fourth quarter of 2015 related to the
discontinuance of a product. Sequentially, operating income
saw slightly higher costs in all categories, offset in part by
increased sales prices.
Corporate
Our general corporate expense decreased slightly on
a year-over-year basis, with some increase in our management
incentive accruals offset by favorable pension and environmental
accruals and lower charges for amortization. Sequentially,
general corporate expense remained relatively flat.
During the fourth and third quarters of 2016, we
recorded $2 million and $11 million, respectively, of merger and
integration costs, which primarily are comprised of legal and other
fees associated with the signing of the Merger Agreement with
Lanxess and the charge related to the Addivant preferred stock
noted below.
Contemporaneous with the execution of the Merger
Agreement, we entered into an agreement with SK Blue Holdings,
Ltd., and Addivant USA Holdings Corp (collectively, "Addivant")
that committed us to surrender our shares of Addivant preferred
stock to Addivant along with a cash payment of $1 million in
exchange for a modification of a non-compete agreement entered into
in conjunction with the sale of our antioxidants business to
Addivant in 2013. Reflecting the terms of this agreement, in
the third quarter of 2016, we took a charge of $5 million which is
included in the merger and integration costs described above.
The agreement with Addivant also provided for certain other
modifications to our continuing supply agreements with Addivant
that are contingent upon the completion of the Merger.
Agrochemical Manufacturing Segment
The Agrochemical Manufacturing segment reported
lower net sales but operating income was relatively flat both
year-over-year and sequentially.
The decrease in net sales was attributable to the
change from a supply agreement to a tolling agreement in Brazil
implemented earlier in 2016 (which reduced both net sales and cost
of sales with no impact on operating profit). We note that
the results include net sales and operating profit related to the
non-cash amortization, net of accretion, of a below-market contract
obligation that is related to our supply agreements. These
amounts were $9 million, $9 million and $10 million in the fourth
quarter of 2016, the fourth quarter of 2015 and the third quarter
of 2016, respectively.
Income Taxes
Income tax expense was $14 million in the fourth
quarter of 2016 compared with a benefit of $27 million in the
fourth quarter of 2015 and expense of $17 million in the third
quarter of 2016. In the fourth quarter of 2015, we released
$19 million of certain remaining U.S. federal and state tax
valuation allowances as a result of our anticipated improvement in
profitability in the U.S. and additional tax benefits were realized
from increased utilization of foreign tax credit carrybacks to 2014
and the use of foreign net operating losses which became available
due to a change in a foreign country's tax law. As a result,
our 2015 effective tax rate was 11%. In 2016, our effective
tax rate for the year was significantly increased by the tax
treatment of the pension settlement accounting arising from the
pension annuity transaction in the first quarter of 2016.
For purposes of calculating our Non-GAAP Earnings
From Continuing Operations, we have applied a Non-GAAP tax rate of
28%. The non-GAAP rate reflects adjustments to our U.S. GAAP
provision to exclude the tax effects of certain types of income and
expense as described in our Non-GAAP Measures policy below.
In the first quarter of 2015, we completed an
evaluation based upon the forecast for the full year and we
estimated our Non-GAAP tax rate to be 28%. This rate was
subject to fluctuations each quarter due to changes in our
forecasted operating results of our continuing businesses, changes
in the mix of income between U.S. and foreign jurisdictions and
discrete items that are recorded in the periods in which they
occur. As 2015 progressed, we revised down our Non-GAAP rate
for the inclusion of credits, deductions and return to provision
adjustments but excluded those that directly related to the
divestiture of Chemtura AgroSolutions. In the fourth quarter
of 2015, the Non-GAAP tax rate was further reduced for additional
tax benefits we obtained. Based on these adjustments to the
effective rate, our Non-GAAP tax rate for the full year of 2015 was
13%. Due to the reduction of the Non-GAAP tax rate from that
used for the third quarter ended September 30, 2015, the resulting
Non-GAAP tax provision for the fourth quarter of 2015 was lower
than the full year rate.
If we exclude the benefit of the adjustments to our
Non-GAAP rate during 2015 for the items discussed above, our
estimated Non-GAAP tax rate in 2015 was 28%. In the first
quarter of 2016, we again estimated our Non-GAAP tax rate at
28%. Each quarter we evaluated whether this estimate should
be revised. As the 2015 adjustments did not reoccur in 2016,
our Non-GAAP tax rate for 2016 remained at 28% during the year and
the Non-GAAP tax rate for the full year of 2016 was essentially the
same as the 28% estimated rate applied during the year.
Cash income taxes paid (net of refunds) for the
fourth quarter of 2016, the fourth quarter of 2015 and the third
quarter of 2016 were $7 million, $4 million and $13 million,
respectively.
Other Highlights
- Net cash provided by operating activities for the fourth
quarter of 2016 was $50 million as compared with $42 million for
the fourth quarter of 2015 and $43 million for the third quarter of
2016. The cash contributions made to our pension and
post-retirement benefit plans in the fourth quarter of 2016, the
fourth quarter of 2015 and the third quarter of 2016 were $3
million, $4 million and $4 million, respectively.
- Net cash provided by operating activities for the full year of
2016 was $137 million as compared with $159 million for the full
year of 2015. The net cash provided by operating activities
for the full year of 2016 was after the deduction of the $35
million cash contribution to our U.S. qualified pension plan made
following the purchase of the pension annuity contract in the first
quarter of 2016 and approximately $9 million in cash merger and
integration costs related to the Lanxess transaction.
Excluding these two items, net cash provided by operating
activities for the full year of 2016 would have been $181
million.
- Capital expenditures for the fourth quarter of 2016 were $26
million compared with $27 million in the fourth quarter of 2015 and
$24 million in the third quarter of 2016.
- Our total debt was $476 million as of December 31, 2016
compared with $511 million as of December 31, 2015. The
decrease is primarily due to a prepayment of $39 million from
cash-on-hand in the second quarter of 2016 on our senior secured
term loan. Debt as reported in our financial statements
reflected the retrospective change in U.S. GAAP in the first
quarter of 2016 to now report debt net of unamortized debt
financing costs.
- Cash and cash equivalents were $220 million as of
December 31, 2016 compared with $323 million as of
December 31, 2015. The decrease was primarily the result
of capital expenditures, shares repurchased under our share
repurchase program, the $35 million contribution of cash to our
U.S. qualified pension plan in the first quarter of 2016 and a $39
million prepayment against our debt.
Fourth Quarter Earnings Q&A
Teleconference
Copies of this release will be available on the
Investor Relations section of our website at
www.chemtura.com. We will host a teleconference to review
these results at 9:00 a.m. (EST) on Thursday, February 23,
2017. Interested parties are asked to dial in approximately
10 minutes prior to the start time. The call-in number for
U.S. based participants is (877) 494-3128 and for all other
participants is (404) 665-9523. The conference ID code is
48493850.
Replay of the call will be available for thirty
days, starting at 12 p.m. (EST) on Thursday, February 23,
2017. To access the replay, call toll-free (855) 859-2056,
(800) 585-8367, or (404) 537-3406, and enter access code
48493850. An audio webcast of the call can be accessed via
the link below during the time of the call:
http://edge.media-server.com/m/p/6i7ohzsw
Chemtura Corporation, with 2016 net sales of $1.7
billion, is a global manufacturer and marketer of specialty
chemicals. Additional information concerning us is available
at www.chemtura.com.
Non-GAAP Financial Measures
Certain information presented in this press release
and in the attached financial tables includes financial measures
that are not calculated or presented in accordance with Generally
Accepted Accounting Principles in the United States (“GAAP”). We
refer to those financial measures as “Non-GAAP”. While GAAP
provides a prescribed format for presenting financial information,
internally we have developed and use other financial metrics and
measures to make resource allocation decisions, evaluate our
underlying performance, compare that performance to peer companies,
identify operating trends, determine performance-based
compensation, and, among other factors, predict future performance
and cash inflows and outflows. Understanding the Non-GAAP
financial measures we use to manage our business and resources
provides our investors with insights that cannot be obtained by a
review of the GAAP based measures alone. Many of the Non-GAAP
financial measures we use in managing our business can be
calculated by investors and other users of our financial
statements; however, we provide this information to the public to
ensure there are not multiple interpretations of the calculation of
any such measure. To assist our investors in understanding
the differences between our GAAP and Non-GAAP measures, we have
provided a reconciliation between these presentations in the
attached financial tables.
Our Non-GAAP Financial Metrics and policies are
posted on our website at www.Chemtura.com so that they can be
easily referenced by our investors.
We use each of the following Non-GAAP measures to
provide investors and other users of our financial statements with
additional information to aid their understanding of our primary
business performance trends as well as our current and future
potential cash inflows and outflows:
Non-GAAP Net Sales - Included in
our presentation of GAAP Net Sales is the revenue accretion and
amortization of a below market contract liability related to the
supply agreements resulting from the sale of our Chemtura
AgroSolutions business. We excluded these revenues as the
accretion and amortization do not generate current or future cash
flows. We also exclude the benefit of this accretion and
amortization in computing Non-GAAP profitability measures.
Non-GAAP Adjusted EBITDA (Earnings Before
Interest, Taxes, Depreciation and Amortization) -
EBITDA is a financial measure frequently used by investors and
others to understand a company’s profitability as well as its
ability to meet debt service obligations, make investments and
compare performance and valuation to other companies. This
measure excludes cash and non-cash income or charges that exist in
a company’s GAAP presentation that do not necessarily represent
current or future cash inflows or outflows of business
operations. For example, depreciation and amortization are
charges that reduce a company’s net income, but reflect a historic
rather than current use of cash and share-based compensation
expense is a charge where there is no current use of cash.
This pre-tax measure also excludes interest expense as well as
other miscellaneous income and expense, such as realized and
unrealized foreign exchange gains and loss, that we have concluded
are not representative of current performance of our operating
businesses. Our calculation begins with GAAP Net Earnings
(Loss) from which we exclude GAAP income tax expense or benefit,
GAAP interest expense, GAAP depreciation and amortization, GAAP
other income or expense, the non-cash share-based compensation
expense and certain other income and charges as listed in the
description of our Non-GAAP policy below. It is also one of
the performance measures used to determine the amount, if any, of a
payout under our management incentive plans.
Non-GAAP Earnings (Loss) from Continuing
Operations Before Income Taxes - As defined by GAAP,
Earnings (Loss) from Continuing Operations Before Tax is a
sub-total that provides information regarding an entity’s results
of continuing operations excluding any amounts related specifically
to income taxes. It is calculated by taking Net Earnings
(Loss) and excluding any income or loss associated with
discontinued operations and any income tax expense. To
calculate Non-GAAP Earnings (Loss) from Continuing Operations
Before Income Taxes, we start with GAAP Net Earnings (Loss) and
exclude any results related to discontinued operations, income tax
expense and certain other income and charges as listed in the
description of our Non-GAAP policy below. This sub-total is
necessary when computing income tax expense on an interim basis (as
described below) for both GAAP and Non-GAAP purposes.
Non-GAAP Income Tax Expense /
Benefit - The calculation of our GAAP income tax expense
or benefit in any interim period is based upon an estimate of our
effective tax rate for the annual period multiplied by our interim
GAAP Earnings (Loss) from Continuing Operations Before Income
Taxes, adjusted for discrete items if required. The
calculation of our Non-GAAP Income Tax Expense is based on the same
principles as our GAAP income tax expense; however, we exclude from
the calculation any tax associated with items that have been
excluded, or are projected to be excluded during the calendar year,
in our Non-GAAP Earnings (Loss) from Continuing Operations Before
Income Taxes, which are listed in the description of our Non-GAAP
policy below. We also exclude certain tax benefits and
expenses as described in our Non-GAAP policy below.
Application of the GAAP tax rate to our Non-GAAP Earnings (Loss)
from Continuing Operations Before Income Taxes would render an
income tax expense that does not correctly reflect the tax
associated with the pre-tax adjustments we make in our Non-GAAP
performance measures. The computation of an effective tax
rate reflecting the tax effect of our pre-tax Non-GAAP adjustments
permits the calculation of after tax Non-GAAP performance measures
and provides additional insights as to the underlying global tax
rate for our primary business operations. At the end of the
calendar year, we prepare a tax provision based on Non-GAAP
Earnings (Loss) from Continuing Operations Before Income Taxes,
excluding certain tax benefits and expenses as described in our
Non-GAAP policy below, in order to compute Non-GAAP Earnings (Loss)
from Continuing Operations (defined below) for the fourth quarter
and calendar year.
Non-GAAP Earnings (Loss) from Continuing
Operations - This measure is determined by applying
the Non-GAAP Effective Tax Rate for interim periods, or for the
calendar year, a tax provision, to our Non-GAAP Earnings (Loss)
from Continuing Operations Before Income Taxes and reducing the
Non-GAAP Earnings (Loss) from Continuing Operations Before Income
Taxes by that amount. The resulting measure is termed
Non-GAAP Earnings (Loss) from Continuing Operations. This
metric is intended to provide users of the financial statements
with an after tax profitability measure consistent with our pre-tax
Non-GAAP measure and is required to compute Non-GAAP Earnings
(Loss) Per Share from Continuing Operations.
Non-GAAP Earnings (Loss) Per Share from
Continuing Operations - To calculate this Non-GAAP
measure, we divide our Basic and Diluted Weighted Average Shares
into our Non-GAAP Earnings (Loss) from Continuing Operations.
To determine our Basic and Diluted Weighted Average Shares, we
utilize GAAP principles under both presentations. In many
periods, the GAAP and Non-GAAP Basis and Weighted Average Shares
are the same; however, should either the GAAP or Non-GAAP Earnings
(Loss) from Continuing Operations be anti-dilutive, the Diluted
Weighted Averages Shares may differ between the two
presentations. This measure is used as one of the criteria to
determine the amount, if any, of a payout under our management
incentive plans.
Free Cash Flow - We define Free
Cash Flow as Net Cash Provided by (Used in) Operating Activities
less GAAP capital expenditures and investments in intangible assets
as presented in our GAAP Consolidated Statement of Cash
Flows. It is intended to provide users of our financial
statements an indication of cash flows that are generated by or
used in our primary business operations alone. We caution
investors that this measure excludes Net Cash Provided by (Used in)
Financing Activities that can include mandatory debt service
obligations. It will also exclude investments such as
acquisitions or cash proceeds from divestitures. It includes
cash contributions to pension plans and post-retirement benefit
obligations as these are included in Net Cash Provided by (Used in)
Operating Activities. This measure therefore cannot be used
to understand changes in cash or in total indebtedness in any
reporting period.
Net Debt - The term Net Debt is a
Non-GAAP measure that is calculated from information in our GAAP
presentation. We add Short-term Borrowings and Long-term Debt
(combined “Total Debt”) less Cash and cash equivalents, all as
presented on our Condensed Consolidated Balance Sheet. This metric
provides users of our financial statements a view of our
indebtedness were we to use all our cash and cash equivalents on
hand to repay debt.
To ensure consistency in the presentation of these
Non-GAAP measures, we have developed an internal accounting policy
which specifies what types of income or expense are considered to
be adjustments to our GAAP financial results and metrics. In
practice, this policy is reviewed annually and approved by our
Disclosure Committee and the Audit Committee of our Board of
Directors. Our Non-GAAP financial measures have not changed
from the prior year, although in some years we do not have certain
transactions.
In accordance with our Non-GAAP accounting policy,
we adjust our pre-tax GAAP information for the following items:
- costs associated with facility closures, severance and related
costs, including accelerated depreciation due to changes in the
useful life of assets, the accelerated recognition of asset
retirement obligations as a result of facility closures, and any
gain or loss on the disposal of any assets or facility that has
been closed;
- incremental environmental remediation charges resulting from a
facility closure or the sale of a business which are not considered
directly associated with our on-going operations;
- gains and losses on the sale of businesses or the formation of
joint ventures;
- gains or losses related to the early extinguishment of
debt;
- income and expense on legal settlements for any significant
matter or combination of related matters that is considered not
directly associated with our on-going operations;
- income and expense related to a major catastrophic event for
any matter or combination of related matters that is considered not
directly associated with our on-going operations;
- asset impairment charges;
- income or expense directly related to the purchase or sale of a
business which was incurred in the periods prior to the purchase or
sale but adjustments are only made after we have entered into a
definitive agreement and announced the transaction and prior to the
adoption of any discontinued operations treatment, if
applicable;
- income or expense directly associated with the Merger with
Lanxess, including those directly related to the transaction as
well as those directly attributable to the cost of
integration;
- gains or losses on the settlement or curtailment of our pension
plans or post-retirement plans which occurred as a result of
dispositions, mergers or significant plan amendments;
- gains or losses associated with the release of the Cumulative
Translation Adjustment upon the complete or substantial liquidation
of any majority-owned entities;
- revenue or other income associated with the recognition of the
fair value, net of accretion, of the significant below-market
contractual obligations related to the supply agreements with
Platform Specialty Products;
- tax expense or benefit associated with any of the pre-tax items
noted above;
- tax expense associated with the repatriation of net proceeds
resulting from the sale of a business;
- tax expense or benefit related to tax indemnification on the
sale of businesses for periods prior to the sale; and
- establishment or release of valuation allowance related to U.S.
Federal and state net operating losses ("NOLs") and Federal tax
credits generated prior to November 2010 and foreign NOLs of our
subsidiaries primarily related to former businesses.
Although we utilize Non-GAAP financial measures
internally to monitor and analyze our performance, determine
compensation under our management incentive plans and predict
future performance, investors should not consider them to be a
substitute for financial measures prepared in accordance with
GAAP. In addition, these Non-GAAP financial measures may be
calculated differently from similarly titled Non-GAAP financial
measures utilized by other companies and, therefore, should not be
used in a comparison of our performance relative to other companies
without further review of how others calculate these measures.
Forward-Looking Statements
This earnings press release contains
forward-looking statements based on management’s current
expectations, estimates and projections. All statements that
address expectations or projections about the future, including our
actions that will drive earnings growth, demand for our products
and expectations for growth, are forward-looking statements.
These statements are not guarantees of future performance and are
subject to risks, uncertainties, potentially inaccurate assumptions
and other factors, some of which are beyond our control and
difficult to predict. If known or unknown risks materialize,
or should underlying assumptions prove inaccurate, our actual
results could differ materially from past results and from those
expressed in forward-looking statements. Important factors
that could cause our results to differ materially from those
expressed in forward-looking statements include, but are not
limited to, economic, business, competitive, political, regulatory,
legal and governmental conditions in the countries and regions in
which we operate. These factors and others are discussed more
fully in the reports we file with the Securities and Exchange
Commission, particularly our latest annual report on Form
10-K. We assume no obligation to provide revisions to any
forward-looking statements should circumstances change, except as
otherwise required by securities and other applicable laws.
CHEMTURA CORPORATION |
Index of
Financial Statements and Schedules |
|
|
Page |
|
|
GAAP Condensed
Consolidated Statements of Operations (Unaudited) - |
|
Quarters
ended December 31, 2016, September 30, 2016 and December 31,
2015 |
|
and years
ended December 31, 2016 and December 31, 2015 |
9 |
|
|
GAAP Segment
Information (Unaudited) - |
|
Quarters
ended December 31, 2016, September 30, 2016 and December 31,
2015 |
|
and years
ended December 31, 2016 and December 31, 2015 |
10 |
|
|
Condensed Consolidated
Balance Sheets - December 31, 2016 and December 31, 2015 |
11 |
|
|
Condensed Consolidated
Statements of Cash Flows and Supplemental Data (Unaudited) - |
|
Quarters
ended December 31, 2016, September 30, 2016 and December 31,
2015 |
|
and years
ended December 31, 2016 and December 31, 2015 |
12 |
|
|
Major Factors Affecting
Net Sales and Operating Income (Unaudited) - |
|
Quarter
ended December 31, 2016 versus December 31, 2015 and September 30,
2016 |
13 |
|
|
Major Factors Affecting
Net Sales and Operating Income (Unaudited) - |
|
Year
ended December 31, 2016 versus December 31, 2015 |
14 |
|
|
Reconciliation of
Non-GAAP metrics (Unaudited) - |
|
Quarters
ended December 31, 2016, September 30, 2016 and December 31,
2015 |
|
and years
ended December 31, 2016 and December 31, 2015 |
15 |
|
|
Reconciliation of GAAP
Net Earnings (Loss) to Segment and Total Adjusted EBITDA
(Unaudited) - |
|
Quarters
ended December 31, 2016, September 30, 2016 and December 31,
2015 |
16 |
|
|
Reconciliation of GAAP
Net Earnings (Loss) to Segment and Total Adjusted EBITDA
(Unaudited) - |
|
Years
ended December 31, 2016 and December 31, 2015 |
17 |
|
|
Reconciliation of GAAP
Net Earnings (Loss) to Adjusted EBITDA (Unaudited) - |
|
Years
ended December 31, 2016 and December 31, 2015 |
18 |
|
|
CHEMTURA CORPORATION |
Condensed Consolidated Statements of Operations
(Unaudited) |
(In
millions, except per share data) |
|
|
|
Quarters Ended |
|
Years Ended |
|
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
December 31, 2016 |
December 31, 2015 |
|
|
|
|
|
|
|
|
Net sales |
|
$ |
385 |
|
$ |
414 |
|
$ |
399 |
|
|
$ |
1,654 |
|
$ |
1,745 |
|
Cost of goods sold |
|
277 |
|
289 |
|
295 |
|
|
1,181 |
|
1,312 |
|
Gross profit |
|
108 |
|
125 |
|
104 |
|
|
473 |
|
433 |
|
Gross
profit % |
|
28 |
% |
30 |
% |
26 |
% |
|
29 |
% |
25 |
% |
|
|
|
|
|
|
|
|
Selling, general and
administrative |
|
38 |
|
35 |
|
38 |
|
|
143 |
|
151 |
|
Depreciation and
amortization |
|
21 |
|
21 |
|
23 |
|
|
85 |
|
93 |
|
Research and
development |
|
6 |
|
5 |
|
5 |
|
|
21 |
|
20 |
|
Facility closures,
severance and related costs |
|
— |
|
1 |
|
1 |
|
|
1 |
|
3 |
|
Merger and integration
costs |
|
2 |
|
11 |
|
— |
|
|
13 |
|
— |
|
Loss on sale of
business |
|
— |
|
1 |
|
— |
|
|
1 |
|
4 |
|
Impairment charges |
|
— |
|
— |
|
1 |
|
|
1 |
|
1 |
|
Pension settlement |
|
— |
|
— |
|
— |
|
|
162 |
|
— |
|
Equity income |
|
— |
|
— |
|
— |
|
|
— |
|
(1 |
) |
Operating income |
|
41 |
|
51 |
|
36 |
|
|
46 |
|
162 |
|
Interest expense |
|
(8 |
) |
(8 |
) |
(7 |
) |
|
(32 |
) |
(30 |
) |
Other income (expense),
net |
|
3 |
|
(1 |
) |
10 |
|
|
— |
|
20 |
|
Earnings before income
taxes |
|
36 |
|
42 |
|
39 |
|
|
14 |
|
152 |
|
Income tax (expense)
benefit |
|
(14 |
) |
(17 |
) |
27 |
|
|
(29 |
) |
(16 |
) |
Net earnings
(loss) |
|
$ |
22 |
|
$ |
25 |
|
$ |
66 |
|
|
$ |
(15 |
) |
$ |
136 |
|
|
|
|
|
|
|
|
|
Per share
information: |
|
|
|
|
|
|
|
Net earnings (loss) -
Basic |
|
$ |
0.35 |
|
$ |
0.40 |
|
$ |
0.98 |
|
|
$ |
(0.24 |
) |
$ |
2.01 |
|
Net earnings (loss) -
Diluted |
|
$ |
0.34 |
|
$ |
0.39 |
|
$ |
0.96 |
|
|
$ |
(0.24 |
) |
$ |
1.98 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding - Basic |
|
63.0 |
|
63.0 |
|
67.4 |
|
|
63.8 |
|
67.8 |
|
Weighted average shares
outstanding - Diluted |
|
64.1 |
|
63.9 |
|
68.5 |
|
|
63.8 |
|
68.8 |
|
|
|
|
|
|
|
|
|
Comparison versus
September 30, 2016: |
|
|
|
|
|
|
|
% change in net
sales |
|
(7 |
)% |
|
|
|
|
|
% change in operating
income |
|
(20 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparison versus
December 31, 2015: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% change in net
sales |
|
(4 |
)% |
|
|
|
(5 |
)% |
|
% change in operating
income |
|
14 |
% |
|
|
|
(72 |
)% |
|
|
|
|
|
|
|
|
|
CHEMTURA CORPORATION |
Segment Information (Unaudited) |
(In
millions) |
|
|
|
Quarters Ended |
|
Year Ended |
|
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
December 31, 2016 |
December 31, 2015 |
NET
SALES |
|
|
|
|
|
|
|
Petroleum
additives |
|
$ |
131 |
|
$ |
140 |
|
$ |
141 |
|
|
$ |
576 |
|
$ |
614 |
|
Urethanes |
|
57 |
|
63 |
|
57 |
|
|
247 |
|
272 |
|
Industrial Performance Products |
|
188 |
|
203 |
|
198 |
|
|
823 |
|
886 |
|
Bromine based &
related products |
|
130 |
|
142 |
|
134 |
|
|
555 |
|
575 |
|
Organometallics |
|
44 |
|
42 |
|
35 |
|
|
166 |
|
147 |
|
Industrial Engineered Products |
|
174 |
|
184 |
|
169 |
|
|
721 |
|
722 |
|
Agrochemical
Manufacturing |
|
23 |
|
27 |
|
32 |
|
|
110 |
|
137 |
|
Total net
sales |
|
$ |
385 |
|
$ |
414 |
|
$ |
399 |
|
|
$ |
1,654 |
|
$ |
1,745 |
|
|
|
|
|
|
|
|
|
OPERATING
INCOME |
|
|
|
|
|
|
|
Industrial Performance
Products |
|
$ |
26 |
|
$ |
41 |
|
$ |
30 |
|
|
$ |
148 |
|
$ |
141 |
|
Industrial Engineered
Products |
|
23 |
|
28 |
|
17 |
|
|
94 |
|
58 |
|
Agrochemical
Manufacturing |
|
9 |
|
9 |
|
8 |
|
|
37 |
|
35 |
|
Segment
operating income |
|
58 |
|
78 |
|
55 |
|
|
279 |
|
234 |
|
General corporate
expense, including amortization |
|
(15 |
) |
(14 |
) |
(17 |
) |
|
(55 |
) |
(64 |
) |
Facility closures,
severance and related costs |
|
— |
|
(1 |
) |
(1 |
) |
|
(1 |
) |
(3 |
) |
Merger and integration
costs |
|
(2 |
) |
(11 |
) |
— |
|
|
(13 |
) |
— |
|
Loss on sale of
business |
|
— |
|
(1 |
) |
— |
|
|
(1 |
) |
(4 |
) |
Impairment charges |
|
— |
|
— |
|
(1 |
) |
|
(1 |
) |
(1 |
) |
Pension settlement |
|
— |
|
— |
|
— |
|
|
(162 |
) |
— |
|
Total
operating income |
|
$ |
41 |
|
$ |
51 |
|
$ |
36 |
|
|
$ |
46 |
|
$ |
162 |
|
|
|
|
|
|
|
|
|
DEPRECIATION
AND AMORTIZATION |
|
|
|
|
|
|
|
Industrial Performance
Products |
|
$ |
8 |
|
$ |
7 |
|
$ |
7 |
|
|
$ |
30 |
|
$ |
28 |
|
Industrial Engineered
Products |
|
10 |
|
11 |
|
12 |
|
|
42 |
|
47 |
|
Agrochemical
Manufacturing |
|
1 |
|
1 |
|
1 |
|
|
4 |
|
4 |
|
General corporate
expense |
|
2 |
|
2 |
|
3 |
|
|
9 |
|
14 |
|
Total
depreciation and amortization |
|
$ |
21 |
|
$ |
21 |
|
$ |
23 |
|
|
$ |
85 |
|
$ |
93 |
|
|
|
|
|
|
|
|
|
NON-CASH SHARE-BASED COMPENSATION EXPENSE |
|
|
|
Industrial Performance
Products |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
$ |
1 |
|
$ |
1 |
|
Industrial Engineered
Products |
|
— |
|
— |
|
— |
|
|
1 |
|
1 |
|
General corporate
expense |
|
4 |
|
3 |
|
3 |
|
|
11 |
|
10 |
|
Total
non-cash share-based compensation expense |
|
$ |
4 |
|
$ |
3 |
|
$ |
3 |
|
|
$ |
13 |
|
$ |
12 |
|
|
|
|
|
|
|
|
|
CHEMTURA CORPORATION |
Condensed Consolidated Balance Sheets |
(In
millions) |
|
|
|
December 31, 2016 |
|
December 31, 2015 |
|
|
|
|
|
ASSETS |
|
|
|
|
CURRENT ASSETS |
|
|
|
|
Cash and cash
equivalents |
|
$ |
220 |
|
|
$ |
323 |
|
Accounts receivable,
net |
|
213 |
|
|
210 |
|
Inventories, net |
|
310 |
|
|
315 |
|
Other current
assets |
|
122 |
|
|
130 |
|
Total
current assets |
|
865 |
|
|
978 |
|
NON-CURRENT ASSETS |
|
|
|
|
Property, plant and
equipment, net |
|
652 |
|
|
663 |
|
Goodwill |
|
158 |
|
|
166 |
|
Intangible assets,
net |
|
77 |
|
|
88 |
|
Deferred tax asset |
|
305 |
|
|
354 |
|
Other assets |
|
111 |
|
|
111 |
|
Total
Assets |
|
$ |
2,168 |
|
|
$ |
2,360 |
|
|
|
|
|
|
LIABILITIES AND
EQUITY |
|
|
|
|
CURRENT
LIABILITIES |
|
|
|
|
Short-term
borrowings |
|
$ |
19 |
|
|
$ |
46 |
|
Accounts payable |
|
120 |
|
|
120 |
|
Accrued expenses |
|
122 |
|
|
142 |
|
Below market contract
obligation - current |
|
38 |
|
|
38 |
|
Income taxes
payable |
|
11 |
|
|
15 |
|
Total
current liabilities |
|
310 |
|
|
361 |
|
NON-CURRENT
LIABILITIES |
|
|
|
|
Long-term debt |
|
457 |
|
|
465 |
|
Pension and
post-retirement health care liabilities |
|
207 |
|
|
270 |
|
Below market contract
obligation - non-current |
|
107 |
|
|
145 |
|
Deferred tax
liability |
|
6 |
|
|
7 |
|
Other liabilities |
|
103 |
|
|
110 |
|
Total
liabilities |
|
1,190 |
|
|
1,358 |
|
|
|
|
|
|
TOTAL EQUITY |
|
978 |
|
|
1,002 |
|
Total
Liabilities and Equity |
|
$ |
2,168 |
|
|
$ |
2,360 |
|
CHEMTURA CORPORATION |
Condensed Consolidated Statements of Cash Flows and
Supplemental Data (Unaudited) |
(In
millions) |
|
|
|
Quarters Ended |
|
Years Ended |
Increase (decrease) to
cash |
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
December 31, 2016 |
December 31, 2015 |
|
|
|
|
(a) |
|
|
|
Condensed Consolidated Statements of Cash Flows
(Unaudited) |
|
|
|
Net cash provided by
operating activities |
|
$ |
50 |
|
$ |
43 |
|
$ |
42 |
|
|
$ |
137 |
|
$ |
159 |
|
Net cash used in
investing activities |
|
(20 |
) |
(24 |
) |
(27 |
) |
|
(82 |
) |
(23 |
) |
Net cash used in
financing activities |
|
— |
|
(4 |
) |
(3 |
) |
|
(151 |
) |
(189 |
) |
Effect of exchange
rates on cash and cash equivalents |
|
(12 |
) |
1 |
|
(6 |
) |
|
(7 |
) |
(16 |
) |
Change in cash and cash
equivalents |
|
18 |
|
16 |
|
6 |
|
|
(103 |
) |
(69 |
) |
Cash and cash
equivalents at beginning of period |
|
202 |
|
186 |
|
317 |
|
|
323 |
|
392 |
|
Cash and cash
equivalents at end of period |
|
$ |
220 |
|
$ |
202 |
|
$ |
323 |
|
|
$ |
220 |
|
$ |
323 |
|
|
|
|
|
|
|
|
|
Supplemental
cash flow data: |
|
|
|
|
|
|
|
Changes in accounts
receivable |
|
$ |
(4 |
) |
$ |
21 |
|
$ |
16 |
|
|
$ |
(11 |
) |
$ |
24 |
|
Changes in
inventories |
|
$ |
6 |
|
$ |
(15 |
) |
$ |
(2 |
) |
|
$ |
(5 |
) |
$ |
(5 |
) |
Changes in accounts
payable |
|
$ |
— |
|
$ |
— |
|
$ |
(17 |
) |
|
$ |
5 |
|
$ |
(18 |
) |
Changes in pension and
post-retirement health care liabilities |
|
$ |
(3 |
) |
$ |
(4 |
) |
$ |
(3 |
) |
|
$ |
(60 |
) |
$ |
(28 |
) |
|
|
|
|
|
|
|
|
Sale of Platform
shares |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
$ |
— |
|
$ |
54 |
|
Capital
expenditures |
|
$ |
(26 |
) |
$ |
(24 |
) |
$ |
(27 |
) |
|
$ |
(88 |
) |
$ |
(80 |
) |
Payments on long-term
debt |
|
$ |
(3 |
) |
$ |
(1 |
) |
$ |
(1 |
) |
|
$ |
(44 |
) |
$ |
(60 |
) |
Common shares
acquired |
|
$ |
— |
|
$ |
(6 |
) |
$ |
(10 |
) |
|
$ |
(116 |
) |
$ |
(150 |
) |
Income tax payments -
net of refunds |
|
$ |
(7 |
) |
$ |
(13 |
) |
$ |
(4 |
) |
|
$ |
(29 |
) |
$ |
(36 |
) |
Interest payments |
|
$ |
(1 |
) |
$ |
(14 |
) |
$ |
(1 |
) |
|
$ |
(30 |
) |
$ |
(31 |
) |
Cash contributions to
pension and post-retirement health care liabilities |
|
$ |
(3 |
) |
$ |
(4 |
) |
$ |
(4 |
) |
|
$ |
(60 |
) |
$ |
(31 |
) |
|
|
|
|
|
|
|
|
Share
Repurchase Program: |
|
Shares purchased |
Cost of shares |
|
|
|
|
Year ended December 31,
2016 share purchases |
|
4.5 |
|
$ |
116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
Liquidity Measures |
|
|
|
|
|
|
|
|
|
Quarters Ended |
|
Years Ended |
Free Cash
Flow: |
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
December 31, 2016 |
December 31, 2015 |
Net cash provided by
operating activities |
|
$ |
50 |
|
$ |
43 |
|
$ |
42 |
|
|
$ |
137 |
|
$ |
159 |
|
Capital
expenditures |
|
(26 |
) |
(24 |
) |
(27 |
) |
|
(88 |
) |
(80 |
) |
Free Cash
Flow |
|
$ |
24 |
|
$ |
19 |
|
$ |
15 |
|
|
$ |
49 |
|
$ |
79 |
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
|
Capitalization
data: |
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
|
|
Total debt |
|
$ |
476 |
|
$ |
479 |
|
$ |
511 |
|
|
|
|
Cash and cash
equivalents |
|
220 |
|
202 |
|
323 |
|
|
|
|
Net Debt (Total debt
less Cash and cash equivalents) |
|
$ |
256 |
|
$ |
277 |
|
$ |
188 |
|
|
|
|
|
|
|
|
|
|
|
|
CHEMTURA CORPORATION |
Major Factors Affecting Net Sales and Operating Income
(Unaudited) |
(In
millions) |
|
Net Sales |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
Total |
|
|
Quarter Ended
December 31, 2015 |
|
$ |
198 |
|
$ |
169 |
|
$ |
32 |
|
$ |
399 |
|
|
|
Changes in sales
prices |
|
(4 |
) |
6 |
|
— |
|
2 |
|
|
|
Unit volume and
mix |
|
(5 |
) |
— |
|
(9 |
) |
(14 |
) |
|
|
Foreign currency |
|
(1 |
) |
(1 |
) |
— |
|
(2 |
) |
|
|
Quarter Ended
December 31, 2016 |
|
$ |
188 |
|
$ |
174 |
|
$ |
23 |
|
$ |
385 |
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
September 30, 2016 |
|
$ |
203 |
|
$ |
184 |
|
$ |
27 |
|
$ |
414 |
|
|
|
Changes in sales
prices |
|
1 |
|
— |
|
— |
|
1 |
|
|
|
Unit volume and
mix |
|
(16 |
) |
(9 |
) |
(4 |
) |
(29 |
) |
|
|
Foreign currency |
|
— |
|
(1 |
) |
— |
|
(1 |
) |
|
|
Quarter Ended
December 31, 2016 |
|
$ |
188 |
|
$ |
174 |
|
$ |
23 |
|
$ |
385 |
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
General corporate expense |
Other charges (a) |
Total |
Quarter Ended
December 31, 2015 |
|
$ |
30 |
|
$ |
17 |
|
$ |
8 |
|
$ |
(17 |
) |
$ |
(2 |
) |
$ |
36 |
|
Price over raw
materials |
|
— |
|
6 |
|
— |
|
— |
|
— |
|
6 |
|
Unit volume and
mix |
|
(4 |
) |
(1 |
) |
1 |
|
— |
|
— |
|
(4 |
) |
Foreign currency |
|
— |
|
1 |
|
— |
|
— |
|
— |
|
1 |
|
Manufacturing cost and
absorption |
|
(1 |
) |
3 |
|
— |
|
— |
|
— |
|
2 |
|
Distribution cost |
|
2 |
|
(1 |
) |
— |
|
— |
|
— |
|
1 |
|
Depreciation and
amortization expense |
|
(1 |
) |
2 |
|
— |
|
1 |
|
— |
|
2 |
|
Facility closures,
severance and related costs |
|
— |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Merger and integration
costs |
|
— |
|
— |
|
— |
|
— |
|
(2 |
) |
(2 |
) |
Impairment charges |
|
— |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Other |
|
— |
|
(4 |
) |
— |
|
1 |
|
— |
|
(3 |
) |
Quarter Ended
December 31, 2016 |
|
$ |
26 |
|
$ |
23 |
|
$ |
9 |
|
$ |
(15 |
) |
$ |
(2 |
) |
$ |
41 |
|
|
|
|
|
|
|
|
|
Quarter Ended
September 30, 2016 |
|
$ |
41 |
|
$ |
28 |
|
$ |
9 |
|
$ |
(14 |
) |
$ |
(13 |
) |
$ |
51 |
|
Price over raw
materials |
|
(5 |
) |
(1 |
) |
— |
|
— |
|
— |
|
(6 |
) |
Unit volume and
mix |
|
(5 |
) |
(2 |
) |
— |
|
— |
|
— |
|
(7 |
) |
Manufacturing cost and
absorption |
|
(3 |
) |
(1 |
) |
— |
|
— |
|
— |
|
(4 |
) |
Depreciation and
amortization expense |
|
(1 |
) |
1 |
|
— |
|
— |
|
— |
|
— |
|
Facility closures,
severance and related costs |
|
— |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Merger and integration
costs |
|
— |
|
— |
|
— |
|
— |
|
9 |
|
9 |
|
Loss on sale of
business |
|
— |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Other |
|
(1 |
) |
(2 |
) |
— |
|
(1 |
) |
— |
|
(4 |
) |
Quarter Ended
December 31, 2016 |
|
$ |
26 |
|
$ |
23 |
|
$ |
9 |
|
$ |
(15 |
) |
$ |
(2 |
) |
$ |
41 |
|
|
|
|
|
|
|
|
|
(a) -
Includes facility closures, severance and related costs, merger and
integration costs, loss on sale of business and impairment
charges. |
CHEMTURA CORPORATION |
Major Factors Affecting Net Sales and Operating Income
(Unaudited) |
(In millions) |
|
Net Sales |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
Total |
|
|
Year Ended
December 31, 2015 |
|
$ |
886 |
|
$ |
722 |
|
$ |
137 |
|
$ |
1,745 |
|
|
|
Changes in sales
prices |
|
(30 |
) |
12 |
|
— |
|
(18 |
) |
|
|
Unit volume and
mix |
|
(31 |
) |
(14 |
) |
(27 |
) |
(72 |
) |
|
|
Foreign currency |
|
(2 |
) |
1 |
|
— |
|
(1 |
) |
|
|
Year Ended
December 31, 2016 |
|
$ |
823 |
|
$ |
721 |
|
$ |
110 |
|
$ |
1,654 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
General corporate expense |
Other charges (a) |
Total |
Year Ended
December 31, 2015 |
|
$ |
141 |
|
$ |
58 |
|
$ |
35 |
|
$ |
(64 |
) |
$ |
(8 |
) |
$ |
162 |
|
Price over raw
materials |
|
3 |
|
20 |
|
— |
|
— |
|
— |
|
23 |
|
Unit volume and
mix |
|
— |
|
(4 |
) |
2 |
|
— |
|
— |
|
(2 |
) |
Foreign currency |
|
3 |
|
3 |
|
— |
|
— |
|
— |
|
6 |
|
Manufacturing cost and
absorption |
|
2 |
|
13 |
|
— |
|
— |
|
— |
|
15 |
|
Distribution cost |
|
5 |
|
(2 |
) |
— |
|
— |
|
— |
|
3 |
|
Depreciation and
amortization expense |
|
(2 |
) |
5 |
|
— |
|
5 |
|
— |
|
8 |
|
Facility closures,
severance and related costs |
|
— |
|
— |
|
— |
|
— |
|
2 |
|
2 |
|
Merger and integration
costs |
|
— |
|
— |
|
— |
|
— |
|
(13 |
) |
(13 |
) |
Loss on sale of
business |
|
— |
|
— |
|
— |
|
— |
|
3 |
|
3 |
|
Pension settlement |
|
— |
|
— |
|
— |
|
— |
|
(162 |
) |
(162 |
) |
Other |
|
(4 |
) |
1 |
|
— |
|
4 |
|
— |
|
1 |
|
Year Ended
December 31, 2016 |
|
$ |
148 |
|
$ |
94 |
|
$ |
37 |
|
$ |
(55 |
) |
$ |
(178 |
) |
$ |
46 |
|
|
|
|
|
|
|
|
|
(a) -
Includes facility closures, severance and related costs, merger and
integration costs, loss on sale of business, impairment charges and
pension settlement. |
CHEMTURA CORPORATION |
Reconciliation of Non-GAAP Metrics
(Unaudited) |
(In
millions, except per share data) |
|
|
|
Quarters Ended |
|
Years Ended |
|
|
December 31, 2016 |
September 30, 2016 |
December 31, 2015 |
|
December 31, 2016 |
December 31, 2015 |
|
|
|
|
|
|
|
|
Reconciliation
of Non-GAAP Net Sales |
|
|
|
|
|
|
|
Net Sales - GAAP |
|
$ |
385 |
|
$ |
414 |
|
$ |
399 |
|
|
$ |
1,654 |
|
$ |
1,745 |
|
Below
market contract obligation |
|
(9 |
) |
(10 |
) |
(9 |
) |
|
(38 |
) |
(38 |
) |
Net Sales -
Non-GAAP |
|
$ |
376 |
|
$ |
404 |
|
$ |
390 |
|
|
$ |
1,616 |
|
$ |
1,707 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Net Earnings and Non-GAAP
Earnings Per Share |
|
|
|
|
Net earnings (loss) -
GAAP |
|
$ |
22 |
|
$ |
25 |
|
$ |
66 |
|
|
$ |
(15 |
) |
$ |
136 |
|
Below
market contract obligation |
|
(9 |
) |
(10 |
) |
(9 |
) |
|
(38 |
) |
(38 |
) |
Facility
closures, severance and related costs |
|
— |
|
1 |
|
1 |
|
|
1 |
|
3 |
|
Merger
and integration costs |
|
2 |
|
11 |
|
— |
|
|
13 |
|
— |
|
Loss on
sale of business |
|
— |
|
1 |
|
— |
|
|
1 |
|
4 |
|
Impairment charges |
|
— |
|
— |
|
1 |
|
|
1 |
|
1 |
|
Pension
settlement |
|
— |
|
— |
|
— |
|
|
162 |
|
— |
|
Release
of translation adjustment from liquidation of entities |
|
2 |
|
— |
|
(8 |
) |
|
2 |
|
(8 |
) |
Other
adjustments |
|
— |
|
— |
|
— |
|
|
(2 |
) |
2 |
|
Income
tax expense (benefit) |
|
14 |
|
17 |
|
(27 |
) |
|
29 |
|
16 |
|
Net earnings before tax
- Non-GAAP |
|
31 |
|
45 |
|
24 |
|
|
154 |
|
116 |
|
Income
tax (expense) benefit - Non-GAAP |
|
(9 |
) |
(12 |
) |
6 |
|
|
(43 |
) |
(15 |
) |
Net earnings -
Non-GAAP |
|
$ |
22 |
|
$ |
33 |
|
$ |
30 |
|
|
$ |
111 |
|
$ |
101 |
|
|
|
|
|
|
|
|
|
Per share information
(GAAP): |
|
|
|
|
|
|
|
Net earnings (loss) -
Basic |
|
$ |
0.35 |
|
$ |
0.40 |
|
$ |
0.98 |
|
|
$ |
(0.24 |
) |
$ |
2.01 |
|
Net earnings (loss) -
Diluted |
|
$ |
0.34 |
|
$ |
0.39 |
|
$ |
0.96 |
|
|
$ |
(0.24 |
) |
$ |
1.98 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding - Basic |
|
63.0 |
|
63.0 |
|
67.4 |
|
|
63.8 |
|
67.8 |
|
Weighted average shares
outstanding - Diluted |
|
64.1 |
|
63.9 |
|
68.5 |
|
|
63.8 |
|
68.8 |
|
|
|
|
|
|
|
|
|
Per share information
(Non-GAAP): |
|
|
|
|
|
|
|
Net earnings -
Basic |
|
$ |
0.35 |
|
$ |
0.52 |
|
$ |
0.45 |
|
|
$ |
1.74 |
|
$ |
1.49 |
|
Net earnings -
Diluted |
|
$ |
0.34 |
|
$ |
0.52 |
|
$ |
0.44 |
|
|
$ |
1.72 |
|
$ |
1.47 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding - Basic |
|
63.0 |
|
63.0 |
|
67.4 |
|
|
63.8 |
|
67.8 |
|
Weighted average shares
outstanding - Diluted |
|
64.1 |
|
63.9 |
|
68.5 |
|
|
64.7 |
|
68.8 |
|
CHEMTURA CORPORATION |
Reconciliation of GAAP Net Earnings (Loss) to Segment
and Total Adjusted EBITDA (Unaudited) |
(In millions) |
|
Quarter Ended December 31, 2016 |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
Corporate (a) |
Total |
Net earnings (loss) -
GAAP |
|
$ |
26 |
|
$ |
23 |
|
$ |
9 |
|
$ |
(36 |
) |
$ |
22 |
|
Interest
expense |
|
— |
|
— |
|
— |
|
8 |
|
8 |
|
Other
expense, net |
|
— |
|
— |
|
— |
|
(3 |
) |
(3 |
) |
Income
tax expense |
|
— |
|
— |
|
— |
|
14 |
|
14 |
|
Operating income
(loss) |
|
26 |
|
23 |
|
9 |
|
(17 |
) |
41 |
|
Depreciation and amortization |
|
8 |
|
10 |
|
1 |
|
2 |
|
21 |
|
Below
market contract obligation |
|
— |
|
— |
|
(9 |
) |
— |
|
(9 |
) |
Merger
and integration costs |
|
— |
|
— |
|
— |
|
2 |
|
2 |
|
Non-cash
share-based compensation |
|
— |
|
— |
|
— |
|
4 |
|
4 |
|
Adjusted EBITDA |
|
$ |
34 |
|
$ |
33 |
|
$ |
1 |
|
$ |
(9 |
) |
$ |
59 |
|
|
|
|
|
|
|
|
Quarter Ended September 30, 2016 |
|
|
|
|
|
|
Net earnings (loss) -
GAAP |
|
$ |
41 |
|
$ |
28 |
|
$ |
9 |
|
$ |
(53 |
) |
$ |
25 |
|
Interest
expense |
|
— |
|
— |
|
— |
|
8 |
|
8 |
|
Other
expense, net |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Income
tax expense |
|
— |
|
— |
|
— |
|
17 |
|
17 |
|
Operating income
(loss) |
|
41 |
|
28 |
|
9 |
|
(27 |
) |
51 |
|
Depreciation and amortization |
|
7 |
|
11 |
|
1 |
|
2 |
|
21 |
|
Below
market contract obligation |
|
— |
|
— |
|
(10 |
) |
— |
|
(10 |
) |
Facility
closures, severance and related costs |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Merger
and integration costs |
|
— |
|
— |
|
— |
|
11 |
|
11 |
|
Loss on
sale of business |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Non-cash
share-based compensation |
|
— |
|
— |
|
— |
|
3 |
|
3 |
|
Adjusted EBITDA |
|
$ |
48 |
|
$ |
39 |
|
$ |
— |
|
$ |
(9 |
) |
$ |
78 |
|
|
|
|
|
|
|
|
Quarter Ended December 31, 2015 |
|
|
|
|
|
|
Net earnings -
GAAP |
|
$ |
30 |
|
$ |
17 |
|
$ |
8 |
|
$ |
11 |
|
$ |
66 |
|
Interest
expense |
|
— |
|
— |
|
— |
|
7 |
|
7 |
|
Other
income, net |
|
— |
|
— |
|
— |
|
(10 |
) |
(10 |
) |
Income
tax benefit |
|
— |
|
— |
|
— |
|
(27 |
) |
(27 |
) |
Operating income
(loss) |
|
30 |
|
17 |
|
8 |
|
(19 |
) |
36 |
|
Depreciation and amortization |
|
7 |
|
12 |
|
1 |
|
3 |
|
23 |
|
Below
market contract obligation |
|
— |
|
— |
|
(9 |
) |
— |
|
(9 |
) |
Facility
closures, severance and related costs |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Impairment charges |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Non-cash
share-based compensation |
|
— |
|
— |
|
— |
|
3 |
|
3 |
|
Adjusted EBITDA |
|
$ |
37 |
|
$ |
29 |
|
$ |
— |
|
$ |
(11 |
) |
$ |
55 |
|
|
|
|
|
|
|
|
(a)
Includes general corporate expenses, facility closures, severance
and related costs, merger and integration costs, loss on sale of
business and impairment charges. |
CHEMTURA CORPORATION |
Reconciliation of GAAP Net Earnings (Loss) to Segment
and Total Adjusted EBITDA (Unaudited) |
(In millions) |
|
Year Ended December 31, 2016 |
|
Industrial Performance Products |
Industrial Engineered Products |
Agrochemical Manufacturing |
Corporate (a) |
Total |
Net earnings (loss) -
GAAP |
|
$ |
148 |
|
$ |
94 |
|
$ |
37 |
|
$ |
(294 |
) |
$ |
(15 |
) |
Interest
expense |
|
— |
|
— |
|
— |
|
32 |
|
32 |
|
Income
tax expense |
|
— |
|
— |
|
— |
|
29 |
|
29 |
|
Operating income
(loss) |
|
148 |
|
94 |
|
37 |
|
(233 |
) |
46 |
|
Depreciation and amortization |
|
30 |
|
42 |
|
4 |
|
9 |
|
85 |
|
Below
market contract obligation |
|
— |
|
— |
|
(38 |
) |
— |
|
(38 |
) |
Facility
closures, severance and related costs |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Merger
and integration costs |
|
— |
|
— |
|
— |
|
13 |
|
13 |
|
Loss on
sale of business |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Impairment charges |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Pension
settlement |
|
— |
|
— |
|
— |
|
162 |
|
162 |
|
Other
adjustments |
|
— |
|
— |
|
— |
|
(2 |
) |
(2 |
) |
Non-cash
share-based compensation |
|
1 |
|
1 |
|
— |
|
11 |
|
13 |
|
Adjusted EBITDA |
|
$ |
179 |
|
$ |
137 |
|
$ |
3 |
|
$ |
(37 |
) |
$ |
282 |
|
|
|
|
|
|
|
|
Year Ended December 31, 2015 |
|
|
|
|
|
|
Net earnings (loss) -
GAAP |
|
$ |
141 |
|
$ |
58 |
|
$ |
35 |
|
$ |
(98 |
) |
$ |
136 |
|
Interest
expense |
|
— |
|
— |
|
— |
|
30 |
|
30 |
|
Other
income, net |
|
— |
|
— |
|
— |
|
(20 |
) |
(20 |
) |
Income
tax expense |
|
— |
|
— |
|
— |
|
16 |
|
16 |
|
Operating income
(loss) |
|
141 |
|
58 |
|
35 |
|
(72 |
) |
162 |
|
Depreciation and amortization |
|
28 |
|
47 |
|
4 |
|
14 |
|
93 |
|
Below
market contract obligation |
|
— |
|
— |
|
(38 |
) |
— |
|
(38 |
) |
Facility
closures, severance and related costs |
|
— |
|
— |
|
— |
|
3 |
|
3 |
|
Loss on
sale of business |
|
— |
|
— |
|
— |
|
4 |
|
4 |
|
Impairment charges |
|
— |
|
— |
|
— |
|
1 |
|
1 |
|
Other
adjustments |
|
— |
|
1 |
|
— |
|
(1 |
) |
— |
|
Non-cash
share-based compensation |
|
1 |
|
1 |
|
— |
|
10 |
|
12 |
|
Adjusted EBITDA |
|
$ |
170 |
|
$ |
107 |
|
$ |
1 |
|
$ |
(41 |
) |
$ |
237 |
|
|
|
|
|
|
|
|
(a)
Includes general corporate expenses, facility closures, severance
and related costs, merger and integration costs, loss on sale of
business, impairment charges and pension settlement. |
CHEMTURA CORPORATION |
Reconciliation of GAAP Net Earnings (Loss) to Adjusted
EBITDA (Unaudited) |
(In
millions) |
|
|
|
Years Ended |
|
|
December 31, 2016 |
|
December 31, 2015 |
Net (loss) earnings -
GAAP |
|
$ |
(15 |
) |
|
$ |
136 |
|
Interest
expense |
|
32 |
|
|
30 |
|
Other
income, net |
|
— |
|
|
(20 |
) |
Income
tax expense |
|
29 |
|
|
16 |
|
Operating income |
|
46 |
|
|
162 |
|
Depreciation and amortization |
|
85 |
|
|
93 |
|
Below
market contract obligation |
|
(38 |
) |
|
(38 |
) |
Facility
closures, severance and related costs |
|
1 |
|
|
3 |
|
Merger
and integration costs |
|
13 |
|
|
— |
|
Loss on
sale of business |
|
1 |
|
|
4 |
|
Impairment charges |
|
1 |
|
|
1 |
|
Pension
settlement |
|
162 |
|
|
— |
|
Other
adjustments |
|
(2 |
) |
|
— |
|
Non-cash
share-based compensation |
|
13 |
|
|
12 |
|
Adjusted EBITDA |
|
$ |
282 |
|
|
$ |
237 |
|
Contact: Matthew Sokol 203-573-2153
Chemtura Corp. (delisted) (NYSE:CHMT)
Historical Stock Chart
From Dec 2024 to Jan 2025
Chemtura Corp. (delisted) (NYSE:CHMT)
Historical Stock Chart
From Jan 2024 to Jan 2025